Related Experiment Video

Updated: Sep 24, 2025

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

379

Slow and Steady Wins the Race: 25 Years Developing the GLP-1 Receptor as an Effective Target for Weight Loss

Nitya Kumar1, David A D'Alessio1

  • 1Duke University Medical Center, Division of Endocrinology, Metabolism, and Nutrition, Durham, NC 27710, USA.

The Journal of Clinical Endocrinology and Metabolism
|May 10, 2022
PubMed

Insights

Glucagon-like peptide 1 (GLP-1) receptor agonists are effective for weight loss. These agents target the central nervous system to reduce food intake, offering a new therapeutic avenue.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Neuroscience

Background:

  • Glucagon-like peptide 1 (GLP-1) receptor agonists were initially developed for type 2 diabetes management.
  • Extensive research over 30 years reveals their significant impact on central nervous system pathways regulating appetite.
  • This highlights their potential beyond glycemic control.

Purpose of the Study:

  • To review the fundamental biology of GLP-1.
  • To summarize clinical evidence supporting GLP-1 receptor agonists for weight management.
  • To underscore the therapeutic potential of targeting the GLP-1 signaling system.

Main Methods:

  • Literature review of clinical trials and preclinical research on GLP-1 receptor agonists.
  • Analysis of studies investigating GLP-1's role in appetite regulation.
  • Synthesis of data on efficacy and tolerability for weight loss.

Main Results:

  • Clinical trials demonstrate the efficacy and tolerability of GLP-1 receptor agonists for weight loss.
  • Evidence indicates these agents act centrally to decrease food intake.
  • The GLP-1 receptor signaling system is validated as a key target for obesity treatment.

Conclusions:

  • GLP-1 receptor agonists represent a promising therapeutic strategy for weight loss.
  • Understanding GLP-1 biology is crucial for optimizing its use in obesity management.
  • The therapeutic utility of targeting GLP-1 signaling is well-supported by current evidence.
Keywords:
GLP-1 receptor agonistsglucagon-like peptide 1obesityweight loss

More Related Videos

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

9.6K
Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

39.0K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
447
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.7K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
272
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
280
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
318
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.9K